




# PHARMACEUTICAL 2023

Fulcrum Therapeutics Inc.  
Rank 117 of 446





RealRate

# PHARMACEUTICAL 2023

## Fulcrum Therapeutics Inc. Rank 117 of 446



The relative strengths and weaknesses of Fulcrum Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Fulcrum Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Fulcrum Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 182%, being 139% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	207,519
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,725
Liabilities, Non-Current	11,018
Other Assets	12,260
Other Compr. Net Income	-400
Other Expenses	427
Other Liabilities	0
Other Net Income	2,690
Other Revenues	6,342
Property and Equipment	6,906
Research and Development	76,782
Selling, General and Administrative Expense	41,694

Output Variable	Value in 1000 USD
Assets	226,685
Liabilities	27,743
Expenses	118,903
Revenues	6,342
Stockholders Equity	198,942
Net Income	-109,871
Comprehensive Net Income	-110,071
Economic Capital Ratio	182%